vorinostat has been researched along with Hemorrhagic Thrombocythemia in 4 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
Excerpt | Relevance | Reference |
---|---|---|
" We investigated YKL-40 before and after treatment with vorinostat in 31 polycythemia vera (PV) and 16 essential thrombocythemia (ET) patients." | 9.19 | Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat. ( Ahlstrand, E; Andersen, CL; Andreasson, B; Bareford, D; Bjerrum, OW; Bjørn, ME; Ejerblad, E; Fernandes, S; Grønbæk, K; Harrison, C; Hasselbalch, HC; Jensen, MK; Klausen, TW; Knapper, S; Kruse, T; Larsen, H; Linder, O; Löfvenberg, E; McMullin, MF; Mourits-Andersen, T; Samuelsson, J; Skov, V; Thomassen, M; Vestergaard, H; Zweegman, S, 2014) |
" We investigated YKL-40 before and after treatment with vorinostat in 31 polycythemia vera (PV) and 16 essential thrombocythemia (ET) patients." | 5.19 | Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat. ( Ahlstrand, E; Andersen, CL; Andreasson, B; Bareford, D; Bjerrum, OW; Bjørn, ME; Ejerblad, E; Fernandes, S; Grønbæk, K; Harrison, C; Hasselbalch, HC; Jensen, MK; Klausen, TW; Knapper, S; Kruse, T; Larsen, H; Linder, O; Löfvenberg, E; McMullin, MF; Mourits-Andersen, T; Samuelsson, J; Skov, V; Thomassen, M; Vestergaard, H; Zweegman, S, 2014) |
"Treatment with vorinostat resulted in a younger MA in PV patients and older MA in ET patients, in both cases a trend towards the normal chronological age." | 2.90 | Methylation age as a correlate for allele burden, disease status, and clinical response in myeloproliferative neoplasm patients treated with vorinostat. ( Andersen, C; Greenfield, G; Grinfeld, J; Hasselbalch, HC; McMullin, MF; McPherson, S; Mills, KI; Nangalia, J, 2019) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (25.00) | 29.6817 |
2010's | 3 (75.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
McPherson, S | 1 |
Greenfield, G | 1 |
Andersen, C | 1 |
Grinfeld, J | 1 |
Hasselbalch, HC | 3 |
Nangalia, J | 1 |
Mills, KI | 1 |
McMullin, MF | 3 |
Andersen, CL | 2 |
Ejerblad, E | 2 |
Zweegman, S | 2 |
Harrison, C | 2 |
Fernandes, S | 2 |
Bareford, D | 2 |
Knapper, S | 2 |
Samuelsson, J | 2 |
Löfvenberg, E | 2 |
Linder, O | 2 |
Andreasson, B | 2 |
Ahlstrand, E | 2 |
Jensen, MK | 2 |
Bjerrum, OW | 2 |
Vestergaard, H | 2 |
Larsen, H | 2 |
Klausen, TW | 2 |
Mourits-Andersen, T | 2 |
Bjørn, ME | 1 |
Skov, V | 1 |
Thomassen, M | 1 |
Kruse, T | 1 |
Grønbæk, K | 1 |
Lee, J | 1 |
3 trials available for vorinostat and Hemorrhagic Thrombocythemia
Article | Year |
---|---|
Methylation age as a correlate for allele burden, disease status, and clinical response in myeloproliferative neoplasm patients treated with vorinostat.
Topics: Adult; Aged; Aged, 80 and over; Cell Line, Tumor; DNA Methylation; DNA, Neoplasm; Epigenesis, Geneti | 2019 |
A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Fatigue; Female; Gastrointestinal Diseases; Hematologic | 2013 |
Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat.
Topics: Adipokines; Adult; Aged; Aged, 80 and over; C-Reactive Protein; Chitinase-3-Like Protein 1; Female; | 2014 |
1 other study available for vorinostat and Hemorrhagic Thrombocythemia
Article | Year |
---|---|
Clinical efficacy of vorinostat in a patient with essential thrombocytosis and subsequent myelofibrosis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Blood Transfusion; Humans; Hyd | 2009 |